undamentalytics Newsletter

AbbVie balance sheet

At the end of fiscal 2025, AbbVie had total assets of $133.96bn and shareholders' equity of −$3.27bn. It held $5.23bn in cash against $67.50bn of debt: net debt of $62.27bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

AbbVie: balance sheet, annual
Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents0.05.99.68.38.45.19.37.339.98.49.79.212.85.55.210.8
Receivables—4.33.93.74.74.85.15.45.48.810.011.311.210.912.613.5
Inventory—1.11.21.11.71.41.61.61.83.33.13.64.14.25.05.3
Total current assets—15.417.816.116.316.221.216.949.524.227.928.533.025.629.137.5
Goodwill6.16.16.35.913.215.415.815.715.633.132.432.232.335.035.637.8
Total assets—27.029.227.553.166.170.859.489.1150.6146.5138.8134.7135.2134.0147.7
Accounts payable—0.60.91.41.61.41.51.51.52.32.92.93.72.93.6—
Total current liabilities—6.86.911.410.99.816.617.215.628.735.229.537.838.743.343.1
Short-term debt—1.00.40.40.40.40.43.70.00.00.00.00.00.02.50.0
Long-term debt—14.614.310.529.236.431.035.067.284.976.063.159.266.864.572.2
Total debt0.015.714.715.031.736.837.440.367.286.176.763.359.467.167.580.9
Shareholders' equity—−0.44.51.73.94.65.1−8.4−8.213.115.417.310.43.3−3.3−4.6
Net debt (negative = net cash)−0.09.85.16.623.331.728.133.027.377.666.954.146.661.662.370.1

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABBV vs AMGNABBV vs GILDABBV vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from AbbVie's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to AbbVie.